<DOC>
	<DOCNO>NCT02336711</DOCNO>
	<brief_summary>Phase I study assess feasibility ( i.e . early toxicity ) Molecular Imaging-based Dose Escalation HPV Negative Patients With Locally Advanced SCC Oropharynx .</brief_summary>
	<brief_title>Molecular Imaging-based Dose Escalation HPV Negative Patients With Locally Advanced SCC Oropharynx</brief_title>
	<detailed_description>The objective ass feasibility ( i.e . early toxicity ) adaptive dose escalation 18F-FDG-PET-based dose paint number 10 HPV negative patient locally advance squamous cell carcinoma oropharynx . Treatment deliver Helical Tomotherapy® volumetric-modulated arc therapy ( VMAT ) . Dose adaptation perform 2 time-points per-treatment 18F-FDG-PET/CT scan .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Patients older 18 year Patients squamous cell carcinoma oropharynx , HPVnegative ( p16 assay ) T size 3 cm great dimension exclusion tumor bone infiltration N0 , N1 , N2a , N2b node ( AJCC/UICC 7th edition ) No distant metastasis No contraindication concomitant chemotherapy World Health Organization ( WHO ) Performance Status 0 1 Karnofsky performance status ≥ 80 . Provision write informed consent Patients induction chemotherapy eligible Previous concurrent history cancer , except basal cell skin carcinoma Second primary tumor time diagnosis Previous treatment surgery , radiotherapy chemotherapy head neck malignancy Any evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic renal disease ) , psychological disorder Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>